New cocktail of cancer drugs shows promise for tough leukemia cases
NCT ID NCT04169737
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 32 times
Summary
This phase 2 trial is testing whether a combination of three drugs—acalabrutinib, venetoclax, and obinutuzumab—can better control chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) that has come back or is resistant to treatment. About 168 adults with high-risk or relapsed disease will receive either two or three drugs. The main goal is to see if the treatment can clear cancer cells from the bone marrow.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
acalabrutinib, venetoclax, and obinutuzumab
What this could lead to
If successful, this combination could offer a more effective treatment option for people with hard-to-treat CLL or SLL, potentially leading to longer remission without the need for continuous therapy.
What could go wrong
This is a phase 2 trial, so it is still early. The drugs may cause serious side effects like infections or bleeding, and the combination might not work better than existing treatments.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.